NDAORALTABLETPriority Review
Approved
Feb 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
9
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Clinical Trials (5)
A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
Started Oct 2019
11 enrolled
Limb-Girdle Muscular Dystrophy
A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD)
Started Oct 2018
0Duchenne Muscular Dystrophy
Food Effect and Bioavailability of Deflazacort Formulations in Healthy Volunteers
Started Jun 2015
45 enrolled
Healthy Volunteers
An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort
Started Dec 2014
24 enrolled
Duchenne Muscular Dystrophy
A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics
Started Dec 2014
16 enrolled
Hepatic Impairment